Estradiol and the estradiol metabolite, 2-hydroxyestradiol, activate AMP-activated protein kinase in C2C12 myotubes

Obesity

Volumn 16, Issue 6, 2008, Pages 1284-1288

  D'Eon, Tara M ^a   Rogers, Nicole H ^a   Stancheva, Zlatina S ^a   Greenberg, Andrew S ^a  

^a TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYESTRADIOL; 2-HYDROXYESTRADIOL; AMP ACTIVATED PROTEIN KINASES; AMP-ACTIVATED PROTEIN KINASES; DRUG DERIVATIVE; ESTRADIOL; ESTROGEN RECEPTOR; MULTIENZYME COMPLEX; PROTEIN SERINE THREONINE KINASE;

ANIMAL; ARTICLE; CELL LINE; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVATION; METABOLISM; MOUSE; MUSCLE CELL; PHYSIOLOGY; SKELETAL MUSCLE; WEIGHT GAIN;

ANIMALS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ESTRADIOL; MICE; MULTIENZYME COMPLEXES; MUSCLE FIBERS; MUSCLE, SKELETAL; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, ESTROGEN; WEIGHT GAIN;

MURINAE; RODENTIA;

EID: 44449161505     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2008.50     Document Type: Article

References (31)

1. Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 2003;88:2404-2411.
2. Park Y-W, Zhu S, Palaniappan L et al. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2003;163:427-436.
3. Gambacciani M, Ciaponi M, Cappagli B et al. Prospective evaluation of body weight and body fat distribution in early postmenopausal women with and without hormonal replacement therapy. Maturitas 2001;39:125-132.
4. Jensen LB, Vestergaard P, Hermann AP et al. Hormone replacement therapy dissociates fat mass and bone mass, and tends to reduce weight gain in early postmenopausal women: a randomized controlled 5-year clinical trial of the Danish Osteoporosis Prevention Study. J Bone Miner Res 2003;18:333-342.
5. Kritz-Silverstein D, Barrett-Connor E. Long-term postmenopausal hormone use, obesity, and fat distribution in older women. JAMA 1996;275:46-49.
6. Sumino H, Ichikawa S, Yoshida A et al. Effects of hormone replacement therapy on weight, abdominal fat distribution, and lipid levels in Japanese postmenopausal women. Int J Obes Relat Metab Disord 2003;27:1044-1051.
7. Margolis KL, Bonds DE, Rodabough RJ et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia 2004;47:1175-1187.
8. D'Eon TM, Souza SC, Aronovitz M et al. Estrogen regulation of adiposity and fuel partitioning: Evidence of genomic and non-genomic regulation of lipogenic and oxidative pathways. J Biol Chem 2005;280:35983-39991.
9. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 2005;1:15-25.
10. Zhou G, Myers R, Li Y et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167-1174.
11. LeBrasseur NK, Kelly M, Tsao T-S et al. Thiazolidinediones can rapidly activate AMP-activated protein kinase (AMPK) in mammalian tissues. Am J Physiol Endocrinol Metab 2006;291:E175-E181.
12. Minokoshi Y, Kim YB, Peroni OD et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002;415:339-343.
13. Yamauchi T, Kamon J, Minokoshi Y et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8:1288-1295.
14. Banerjee RR, Rangwala SM, Shapiro JS et al. Regulation of fasted blood glucose by resistin. Science 2004;303:1195-1198.
15. Pold R, Jensen LS, Jessen N et al. Long-term AICAR administration and exercise prevents diabetes in ZDF rats. Diabetes 2005;54:928-934.
16. Simpson ER, McInnes KJ. Sex and fat-can one factor handle both? Cell Metab 2005;2:346-347.
17. Philips BJ, Ansell PJ, Newton LG et al. Estrogen receptor-independent catechol estrogen binding activity: protein binding studies in wild-type, estrogen receptor-α KO, and aromatase KO mice tissues. Biochemistry 2004;43:6698-6708.
18. Shih HH, Tevosian SG, Yee AS. Regulation of differentiation by HBP1, a target of the retinoblastoma protein. Mol Cell Biol 1998;18:4732-4743.
19. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25:402-408.
20. Mikhailova ON, Gulyaeva LF, Filipenko ML. Gene expression of drug metabolizing enzymes in adult and aged mouse liver: a modulation by immobilization stress. Toxicology 2005;210:189-196.
21. Smith C, Stamm SC, Riggs JE et al. Ethanol-mediated CYP1A1/2 induction in rat skeletal muscle tissue. Exp Mol Pathol 2000;69:223-232.
22. Dubey RK, Tofovic SP, Jackson EK. Cardiovascular pharmacology of estradiol metabolites. J Pharmacol Exp Ther 2004;308:403-409.
23. Bjornstrom L, Sjoberg M. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol 2005;19:833-842.
24. Razandi M, Pedram A, Greene GL, Levin ER. Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERα and ERβ expressed in Chinese hamster ovary cells. Mol Endocrinol 1999;13:307-319.
25. Kelly MJ, Levin ER. Rapid actions of plasma membrane estrogen receptors. Trends Endocrinol Metab 2001;12:152-156.
26. Evinger AJ III, Levin ER. Requirements for estrogen receptor α membrane localization and function. Steroids 2005;70:361-363.
27. Dubey RK, Jackson EK, Gillespie DG et al. Cytochromes 1A1/1B1- and catechol-O-methyltransferase-derived metabolites mediate estradiol-induced antimitogenesis in human cardiac fibroblast. J Clin Endocrinol Metab 2005;90:247-255.
28. Bergeron R, Ren JM, Cadman KS et al. Chronic activation of AMP kinase results in NRF-1 activation and mitochondrial biogenesis. Am J Physiol Endocrinol Metab 2001;281:E1340-E1346.
29. Tofovic SP, Dubey RK, Jackson EK. 2-Hydroxyestradiol attenuates the development of obesity, the metabolic syndrome, and vascular and renal dysfunction in obese ZSF1 rats. J Pharmacol Exp Ther 2001;299:973-977.
30. Zhang X, Jia Y, Jackson EK, Tofovic SP. 2-Methoxyestradiol and 2-ethoxyestradiol retard the progression of renal disease in aged, obese, diabetic ZSF1 rats. J Cardiovasc Pharmacol 2007;49:56-63.
31. Schulz E, Anter E, Zou M-H, Keaney JF Jr. Estradiol-mediated endothelial nitric oxide synthase association with heat shock protein 90 requires adenosine monophosphate-dependent protein kinase. Circulation 2005;111:3473-3480.